Furthermore, as the tumor microenvironment limits TCR activation, due to direct disruption of TCR signal transduction (58) or the general low avidity of tumor-associated self-antigens (59), OMCPmutIL-2 represents a unique immunostimulatory agent that can augment CD8+ T cell recognition of antigens. This evidence concerns the gene CD8A and neoplasm.